title: [Prognostic Factors of Stage 3 Colorectal Cancer in 433 Patients].
abstract: OBJECTIVE
  To summarize the prognostic factors of stage 3 colorectal cancer.
  
  
  METHODS
  The clinical data of 433 patients with stage 3 colorectal cancer who were admitted to our hospital from January 2005 to December 2008 for radical surgery and adjuvant chemotherapy were retrospectively analyzed. Relationship of their clinicopathologic features and treatment with the prognosis were analyzed.
  
  
  RESULTS
  Of these 433 stage 3 patients,the mean disease-free survival was (72.37 ± 2.11) months and mean overall survival was (79.91 ± 2.02) months; however, the median survival times were not reached. The 1-,3-, and 5-year disease-free survival rate were 86.8%,77.9%, and 57.0% and the overall survival rate were 91.5%,75.1%, and 63.3%. Multivariate COX regression analysis displayed that intestine obstruction before surgery, complications after surgery,tumor location,positive surgical margin, neural cell infiltration,vessel cancer embolus, TNM stage, lymph node ratio, adjuvant chemotherapy regimens, and chemotherapy duration were the independent factors affecting disease-free and overall survivals in patients with stage 3 colorectal cancer. The efficacies of FOLFOX and XELOX regimens were significantly correlated with patient's age, complications,tumor location,and chemotherapy duration.
  
  
  CONCLUSIONS
  Complications,tumor location, TNM stage, and positive surgical margin are the independent prognostic factors of stage 3 colorectal cancer. FOLFOX and XELOX regimen can remarkably improve prognosis,and a longer duration of chemotherapy can achieve better survival.
authors.affiliation: Second Department of Oncology,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: De-cong
authors.initials: DC
authors.lastname: Sun
authors.affiliation: Second Department of Oncology,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Hui
authors.initials: H
authors.lastname: Mao
authors.affiliation: Second Department of Oncology,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Zhi-kuan
authors.initials: ZK
authors.lastname: Wang
authors.affiliation: Second Department of Oncology,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Shi
authors.affiliation: Second Department of Oncology,Chinese PLA General Hospital,Beijing 100853,China.
authors.forename: Guang-hai
authors.initials: GH
authors.lastname: Dai
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms; D003841:Deoxycytidine / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008198:Lymph Nodes; D009367:Neoplasm Staging; D010071:Oxaloacetates; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil